Healthcare & Medical Services Reservations open Page created Nov 9, 2026

List of FACT Accredited Cell Therapy Centers

FACT-accredited hematopoietic transplant, immune effector cell (CAR-T) and cord blood programs across the Americas, Europe, the Middle East and Asia-Pacific, with country, city, accredited clinical services, collection and processing services and the FACT standards each organization holds. Built for cell therapy site onboarding, supplier targeting and trial feasibility.

Fields we plan to include

Organization
Country
State / province
City
Clinical services
Transplant types
Apheresis collection services
Marrow collection services
Processing types
Service provider type
FACT standards
Accredited collection sites
Cord blood types
FACT directory page

Data Preview

* Free sample rows, unverified and may contain errors. This list isn't for sale yet.
OrganizationCityCountryClinical services
Tennessee OncologySourceNashvilleUSAImmune Effector Cellular Therapy
Hoag Family Cancer InstituteSourceNewport BeachUSAImmune Effector Cellular Therapy
King Abdulaziz Medical City – Riyadh, Saudi ArabiaSourceRiyadhSaudi ArabiaHematopoietic Progenitor Cell Transplantation; Immune Effector Cellular Therapy
Fiona Stanley Hospital Blood and Marrow Transplant ProgramSourcePerthAustraliaHematopoietic Progenitor Cell Transplantation; Immune Effector Cellular Therapy
National University Health System, Haematopoietic Stem Cell Transplantation & Cellular Therapy ProgramSourceSingaporeSingaporeHematopoietic Progenitor Cell Transplantation; Immune Effector Cellular Therapy

Estimated ~350 entries. If people reserve it, we'll try to compile it (we can't compile every list).

* No charge now. Purchase is optional.

FACT accreditation for cell therapy programs: what it certifies and how to read it

The Foundation for the Accreditation of Cellular Therapy (FACT) is a non-profit co-founded by the International Society for Cell & Gene Therapy (ISCT) and the American Society for Transplantation and Cellular Therapy (ASTCT). It accredits clinical programs, collection facilities and processing laboratories that handle hematopoietic progenitor cells and immune effector cells such as CAR-T, as well as cord blood banks. Each accreditation names the services and the standards a program was inspected against, which tells a manufacturer or sponsor far more than a hospital-level quality label.

The standards behind each accreditation

Label in FACT's directoryCurrent standards documentWho holds it
FACT-JACIE Hematopoietic Cellular TherapyFACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration, Ninth EditionBlood and marrow transplant programs and the collection and processing facilities that serve them
FACT Immune Effector Cell Therapy; FACT Immune Effector Cell Therapy (Stand-alone)FACT-JACIE International Standards for Immune Effector Cells, Third EditionCAR-T and other immune effector cell programs and laboratories; "Stand-alone" marks organizations accredited under these standards on their own (seven on 10 November 2026)
FACT Standards for Immune Effector Cells in the Community Clinical SettingFirst Edition, published November 2025Community-based programs administering immune effector cell therapies
FACT Common StandardsFACT Common Standards for Cellular Therapies, Third EditionCell manufacturing and processing facilities (six on 10 November 2026)
NetCord-FACT Cord Blood BankingNetCord-FACT International Standards for Cord Blood Collection, Banking, and Release for Administration, Eighth Edition (Version 8.2)Cord blood banks

FACT accreditation is valid for three years. Programs start the renewal process around their second anniversary, renewal includes an on-site inspection, and collection sites that serve a clinical program are inspected together with that program.

Reading an accreditation entry

  • Clinical services: Hematopoietic Progenitor Cell Transplantation, Immune Effector Cellular Therapy, or both. Many transplant programs show immune effector cell therapy as a clinical service while their standard reads FACT-JACIE Hematopoietic Cellular Therapy, so the clinical service is a better signal of CAR-T capability than the standard name alone.
  • Transplant types: adult or pediatric, allogeneic or autologous. An adult-autologous-only program and a combined adult and pediatric allogeneic center are different partners for referral and trial placement.
  • Apheresis and marrow collection: "Collection for Administration" and "Collection for Further Manufacturing". The second is the one that matters for products manufactured from a patient's own cells, such as autologous CAR-T made from a leukapheresis collection.
  • Processing types: "Minimal Manipulation" and "More than Minimal Manipulation". The latter covers processing that alters the cells' relevant biological characteristics and points to laboratories with deeper manufacturing capability.
  • Service providers and accredited collection sites: some organizations, including American Red Cross apheresis units, are accredited as collection or processing service providers, and FACT names the hospitals where their collection sites are. The American Red Cross program in Philadelphia, for example, has an accredited collection site at Nemours Children's Hospital in Wilmington, Delaware.
  • Cord blood types: related, unrelated, or currently not accepting new cord blood units.

Where the accredited programs are

On 10 November 2026 FACT's public directory showed 353 accredited organizations: 303 in its cellular therapy category and 50 cord blood banks. 261 were in the USA, and the rest were spread over 28 other countries and territories, among them Argentina, Australia, Brazil, Canada, China, India, Jordan, Saudi Arabia, Singapore, Taiwan, Turkey and the United Arab Emirates. 222 organizations showed Hematopoietic Progenitor Cell Transplantation and 205 showed Immune Effector Cellular Therapy as a clinical service. FACT's recent announcements of national or regional firsts include King Hussein Cancer Center in Jordan (July 2026), Ramaiah Memorial Hospital in South India (April 2026) and Hospital Auxilio Mutuo with the American Red Cross Puerto Rico Region (April 2026).

CAR-T after the REMS: why accreditation still shapes networks

On 27 June 2025 the FDA eliminated the Risk Evaluation and Mitigation Strategies for six autologous CD19- and BCMA-directed CAR-T products: Abecma, Breyanzi, Carvykti, Kymriah, Tecartus and Yescarta. Hospitals and clinics dispensing them no longer need REMS certification or on-site, immediate access to tocilizumab, while boxed warnings and medication guides stay in the labeling. That removed a regulatory gate; it did not remove the need for manufacturers, payers and sponsors to judge a site's quality system, and FACT accreditation is an inspected, service-specific form of evidence for that judgement.

The community setting is where the map is moving. FACT published its first-edition Standards for Immune Effector Cells in the Community Clinical Setting in November 2025, adapted from the FACT-JACIE immune effector cell standards, and on 1 September 2026 announced Tennessee Oncology as the first community-based oncology program accredited under them. On 10 November 2026 two organizations in the directory carried that standard.

Accreditation is also not the whole treating population. Real-world analyses presented by Florida Cancer Specialists & Research Institute at the 2026 ASCO Annual Meeting found similar quality and safety measures at accredited and non-accredited CAR-T sites; the authors cautioned that accreditation status alone may not fully capture a center's ability to administer CAR-T safely, and that the finding needs confirmation in further studies. For network planning, accredited programs are the inspected core, and non-accredited treaters are a separate segment to qualify on their own evidence.

Practical checks

  • Accreditation attaches to a named program and to the services and standards shown for it, not to every department of the hospital that houses it.
  • Program names change with mergers and rebranding, and directory addresses can keep an older name: the AdventHealth Orlando transplant and cellular therapy program sits at a URL that still reads "florida-hospital".
  • Because accreditation runs on a three-year cycle, confirm current status in FACT's directory before contracting a site or naming it in a protocol.
  • An accredited collection site can be in a different city or state from the program that holds the accreditation, which matters for courier routing and chain-of-identity planning.

Frequently Asked Questions

Q.What is the difference between FACT-JACIE and FACT immune effector cell accreditation?

FACT-JACIE Hematopoietic Cellular Therapy accreditation is based on the FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration, now in their ninth edition, and is held by transplant programs and the facilities that collect and process cells for them. Immune effector cell accreditation uses the FACT-JACIE International Standards for Immune Effector Cells, now in their third edition. Many transplant programs show Immune Effector Cellular Therapy as a clinical service under their FACT-JACIE accreditation, while organizations accredited under the immune effector cell standards alone carry the label "Stand-alone" on FACT's website.

Q.What does "Collection for Further Manufacturing" mean in a FACT accreditation?

FACT distinguishes apheresis and marrow collection for administration from collection for further manufacturing. The second applies when the collected cells are starting material for a product that is manufactured further before it is given to the patient, as with autologous CAR-T made from a leukapheresis collection. For apheresis, cryopreservation and courier suppliers it is the clearest marker of sites that handle CAR-T starting material.

Q.Can community oncology practices earn FACT accreditation for CAR-T?

Yes. FACT published the first edition of its Standards for Immune Effector Cells in the Community Clinical Setting in November 2025, adapting the FACT-JACIE immune effector cell standards for community programs. On 1 September 2026 FACT announced Tennessee Oncology as the first community-based oncology program accredited under them.

Q.Can I buy the list now?

Not yet. Sample rows are free. We try to compile lists that people reserve (we can't compile every list). If we do, we'll email everyone who reserved it a purchase link (buying is optional). If we don't, nothing happens and you're never charged.

Q.What does it cost?

Sample rows are free. A list is $49, paid only if we compile it and you decide to buy. There is no free trial or subscription.